JOHANNESBURG, SOUTH AFRICA -- (Marketwire) -- 11/09/10 -- www.wallstreetequityresearch.com brings investors market knowledge on the aspects moving the drug related products stocks, and offers complete analytical research on companies like Salix Pharmaceuticals Ltd. (NASDAQ: SLXP) and Perrigo Co. (NASDAQ: PRGO). Register with www.wallstreetequityresearch.com today to gain full access to our complimentary research on these drug related products stocks.
Some struggling drug manufacturers are pursuing alternate means to generate sales volume of their products lately. Instead of massive investments into the research and development of new drugs, some are investing into new ways of using the ones they already have.
www.wallstreetequityresearch.com is a specialized website where investors can have specific access to complimentary reports on drug related products industry; traders looking for analysis on Salix Pharmaceuticals Ltd., Perrigo Co. and other players in the industry are welcomed to sign up for free at http://www.wallstreetequityresearch.com/.
This strategy is paying dividends for drug manufacturers operating at a loss. Some of the recently approved treatments are a far cry from their initial intentions. Salix Pharmaceuticals Ltd., for instance, was approved by the FDA to market its traveler's sickness medication to patients suffering from advanced liver disease. The same drug is now undergoing preliminary trials for its use in treating irritable bowel syndrome. Investors can register today at http://wallstreetequityresearch.com/November092010SalixPharmaceuticalsLtd.(SLXP)091110.php to download the full report on Salix Pharmaceuticals Ltd.
Other struggling drug companies are eyeing the volume approach as well and are copying some trends seen in retail. Like retailers, some drug makers such as Perrigo Co. are capitalizing on more cost conscious consumers and are shifting efforts to discount products to generate revenues and sales volume. Investors can access free research on Perrigo Co. now by signing up at http://wallstreetequityresearch.com/November092010PerrigoCo.(PRGO)091110.php.
Overall, the strategies of expanding application and discounting prices are working well for drug manufacturers who incurred losses during the economic downturn. The long-term success of these plans remains to be seen but they have allowed many companies to pay down debt and generate revenue in the short-term. Visit us at http://www.wallstreetequityresearch.com/ to understand the catalysts and forces driving or affecting companies in the drug related products industry.
On the earnings front for the industry, both Salix Pharmaceuticals Ltd. and Perrigo Co. posted their financial results this month. Perrigo released its earnings last week with net income of $74 million on revenue of $641 million. Conversely, Salix Pharmaceuticals posted its results yesterday with revenue growing by 53% to $80.6 million on the back strong sales of Xifaxan which accounted for $65.2 million of total revenue.
About Wall Street Equity Research:
Wall Street Equity Research looks to bring simplicity and highly sophisticated research to an ever-changing investing environment. Wall Street Equity Research has been partnering with a number of North American and Emerging Economies analysts to bring you the best of both continents in terms of market analysis and analytical opinions.
Contact Person:
Edward D. Brooks
info@wallstreetequityresearch.com